| Product NDC: | 55154-9668 |
| Proprietary Name: | Lotrel |
| Non Proprietary Name: | amlodipine besylate and benazepril hydrochloride |
| Active Ingredient(s): | 10; 40 mg/1; mg/1 & nbsp; amlodipine besylate and benazepril hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 55154-9668 |
| Labeler Name: | Cardinal Health |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020364 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19950303 |
| Package NDC: | 55154-9668-8 |
| Package Description: | 2400 CAPSULE in 1 BOTTLE, PLASTIC (55154-9668-8) |
| NDC Code | 55154-9668-8 |
| Proprietary Name | Lotrel |
| Package Description | 2400 CAPSULE in 1 BOTTLE, PLASTIC (55154-9668-8) |
| Product NDC | 55154-9668 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | amlodipine besylate and benazepril hydrochloride |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19950303 |
| Marketing Category Name | NDA |
| Labeler Name | Cardinal Health |
| Substance Name | AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE |
| Strength Number | 10; 40 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE] |